Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01103349 · ClinicalTrials.gov registry record · Phase 2
BI 671800 in Asthmatic Patients on Inhaled Corticosteroids
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 243
- Enrollment target
NCT01103349 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 243 participants.
The verdict
NCT01103349, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 243 participants
- Enrollment target
Study Summary
This is a 6 week study to assess the effect of BI 671800 in patients with asthma. It is a double blind, parallel arm trial testing the safety and efficacy of BI 671800. The main objective is to assess the effect on lung function. The study will also provide data on the pharmacokinetics of BI 671800.
Interventions
- DRUG Placebo
- DRUG Montelukast
- DRUG BI 671800
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 2010-04-20 |
| Est. Completion | 2011-08-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01103349
The ClinicalTrials.gov registry entry for NCT01103349 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 243 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01103349 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01103349 about?
NCT01103349 is a clinical study titled "BI 671800 in Asthmatic Patients on Inhaled Corticosteroids". This is a 6 week study to assess the effect of BI 671800 in patients with asthma. It is a double blind, parallel arm trial testing the safety and efficacy of BI 671800. The main objective is to assess the effect on lung function. The study will also provide data on the pharmacokinetics of BI 671800.
What is the current status of trial NCT01103349?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 243 participants. The study started on 2010-04-20. Estimated completion is 2011-08-09.
What interventions are being tested in trial NCT01103349?
The interventions under investigation include: Placebo (DRUG), Montelukast (DRUG), BI 671800 (DRUG).
Who is sponsoring clinical trial NCT01103349?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.